1PEROU C M, SORLIE T, EISEN M B, et al. Molecular portraits of human hreast tumours [J]. Nature, 2000, 406(6797): 747-752.
2SORLIE T, TIBSHIRANI R, PARKER J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets [J]. Proc Nat! Acad Sci USA, 2003, 100(14): 8418-8423.
3SORLIE T, PEROU C M, TIBSHIRANI R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci USA, 2001, 98(19): 10869-10874.
4GOLDHIRSCH A, WOOD W C, COATES A S, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the SI. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J] . Ann Oncol, 20 II , 22(8): 1736-1747.
5OAKMAN C, VIALE G, nr LEO A. Management of triple negative breast cancer [J]. Breast, 2010,19(5): 312-321.
6GAZINSKA P, GRIGORIADIS A, BROWN J P, et al. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles [J]. Mod Pathol, 2013, 26: 955-966.
7NIELSEN T O, HSU F D, JENSEN K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004, 10(16): 5367-5374.
8DIALLO-DANEBROCK R, TING E, GLUZ O, et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy [J]. Clin Cancer Res, 2007,13(2 Pt 1): 488-497.
9PEROU C M. Molecular stratification of triple-negative breast cancers [J]. Oncologist, 2011, 16(Suppl 1): 61-70.
10PRAT A, ADAMO B, CHEANG M C, et al. Molecular characterization of basal-like and non-basal-like triple?negative breast cancer [J]. Oncologist, 2013, 18(2): 123- 133.
